

FY2025 Year to Date Financial Summary


(July – March 2025)

Total Revenues	\$ 412.1M
Total Expenses	<u>\$ -408.7M</u>
Operating Gain/(Loss)	\$ 3.4M
Investment Income	<u>\$ 2.2M</u>
Change in Net Position	\$ 5.6M

FY2024 Year End Net Assets	\$ 33.8M
FY2025 YTD Change Net Assets	<u>\$ 5.6M</u>
FY2025 Net Assets (03/31/25)	<u>\$ 39.4M *</u>

*unaudited

FY'25 vs FY'24 Revenues and Expenses*



*Monthly expenses shown reflect a consistent estimate of claims that are incurred but not yet paid (IBNP). Monthly paid claim fluctuations are reflected in this exhibit, but changes in actual monthly IBNP reserves are not. Therefore, actual monthly expenses (paid claims + change in IBNP reserves) may be higher or lower than demonstrated in this exhibit. The purpose of the exhibit is to demonstrate that while contributions are consistent from month to month, expenses fluctuate.

FY2025 Monthly Performance

(\$'s in millions)

FY2025 Month	Operating Gain/(Loss)	Investment Income	Change in Net Position
July	\$ 1.3	\$ 0.6	\$ 1.9
August	(1.7)	0.4	(1.3)
September	5.6	0.4	6.0
October	1.2	(0.3)	0.9
November	(3.4)	0.4	(3.0)
December	(2.3)	(0.2)	(2.5)
January	(2.4)	0.2	(2.2)
February	1.6	0.6	2.2
March	3.5	0.1	3.6
Total Year to Date	\$ 3.40	\$ 2.20	\$ 5.60

*Monthly operating gain/(loss) and change in net position do not reflect any changes in incurred but not paid (IBNP) claim reserves which may indicate that operating gain/(loss) and change in net position may be higher or lower than demonstrated in this exhibit.

FY2025 Performance By Coverage Line

YTD Change in Net Position..... \$5.6M

January Renewal \$1.9M


July Renewal..... \$2.6M

Dental Renewal..... \$1.0M


STD Renewal..... \$0.1M

Key Metrics at a glance (Medical)

12 Months Paid Claims(Apr'24 – Mar'25)




6 Months Paid Claims (Oct'24 – Mar'25)



Key Metrics at a glance (Rx)

12 Months Paid Claims (Apr'24 – Mar'25) 6 Months Paid Claims (Oct'24 – Mar'25)



*Specialty prescriptions represented 53.4% of total gross cost and comprised 1.5% of all prescriptions.

Top specialty drug classes are Oncology, Psoriasis, and Crohns disease.

**Top non-specialty classes are Anti-Obesity, Antidiabetics (Wegovy, Zepbound).

Budget and Investments Update

Budget: Actual operating expenses thru March were approximately 4% or \$362K under the approved budget. Surpluses were primarily the result of turnover, delays in hiring and the timing of projects. Overages in investment services are due to the larger than anticipated investment portfolio balances, while legal services are over budget due to responding to BSR investigations and a subpoena.

Capital Expenses are also under budget by 23% or \$54K due to the timing of projects and related expenses. Laptop and monitor replacements are planned to occur in the fourth quarter of the fiscal year.

Investments: All fixed income securities in our portfolio comply with the investment policy with the exception of the duration of the portfolio, (2.1 years), being below the benchmark's duration, (4.2 years), which is intentional to ensure adequate liquidity, especially as we enter the fourth quarter of the fiscal year.

In March 2025, the bond market experienced modest movements amid economic uncertainty and evolving investor sentiment, resulting in a slight decrease in the value of the portfolio of approximately \$55K.

The FY2025 year-to-date unrealized loss on the fixed income security portfolio through March totaled -\$2.6M, which is improved from the unrealized loss at the end of the previous fiscal year of -\$3.3M.

Cash Management Update

Section 6 of our Investment Policy provides details regarding our cash requirements on a monthly and quarterly basis.

6.1.2 Cash and Cash Equivalents

The amount of cash and cash equivalents shall meet or exceed the larger of the following:

- (a) 50% of one month's contributions; or
- (b) 50% of claims and administration reserve.

In the event of reserve and/or claim fluctuations, a reasonable period of time will be provided to adjust cash balances to meet this requirement.

CASH MANAGEMENT UPDATE

Section 6.1.2 is tested monthly for compliance, (see below).

	Monthly Requirement		Actual		6.1.2 Compliant
	50% Contributions	50% Claims & Admin Reserve	Cash & Equivalents		
July	\$ 23,004,124	\$ 16,676,558	\$ 33,548,697		Yes
August	23,121,594	16,695,154	35,098,641		Yes
September	22,954,598	16,687,079	45,451,720		Yes
October	23,173,340	16,766,057	44,750,184		Yes
November	23,020,571	16,766,710	46,164,241		Yes
December	23,024,802	16,779,743	44,819,500		Yes
January	22,496,220	16,642,642	44,622,583		Yes
February	22,417,771	16,654,541	45,904,175		Yes
March	22,367,349	16,621,986	60,886,167		Yes

Cash Management Update

6.1.3 Investment Maturity Short-term Portfolio

Investments, together with cash and cash equivalents, shall be funded at 100% of the claims and administration reserves.

These investments must have an average life of three years or less.

Quarterly, the HealthTrust CFO will provide the investment manager the amount of portfolio under management that must be invested to meet this target.

In the event of reserve and/or claim fluctuations, a reasonable period of time will be provided to adjust balances to meet this requirement.

Cash Management Update

Section 6.1.3 is tested quarterly for compliance, (see below).

Quarter Ending	Quarterly Requirement		Actual		6.1.3 Compliant
	100%		Cash, Equivalents & Short-Term Investments		
	Claims & Admin Reserve				
Q1: 9/30/24	\$	33,374,157	\$	56,431,220	Yes
Q2: 12/31/24		33,559,486		55,266,427	Yes
Q3: 3/31/25		33,243,971		74,736,912	Yes

We continue to monitor cash levels on a daily basis and are actively modeling and projecting future cash needs, and will work with our Investment Managers and Investment Advisor to raise any funding required in the future to ensure compliance with the policy requirements.